Once Daily Bromday Drops From ISTA Approved For Cataract Patients
October 17, 2010
Submit Comments
ISTA Pharmaceuticals announced yesterday that the FDA has approved BROMDAY(TM) (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. ISTA expects to launch BROMDAY (formerly referred to as XiDay) prior to the end of 2010.
The company expects that the convenience of a once-daily eye drop will help with treatment compliance and benefit patients recovering from cataract surgery.
Click here for the full press release.
Comments
Jump down to form below to submit your own comments
